Jeffrey M. Peters

Articles in Scholarly Journals [Incomplete List]

  1. A Role for PPARß/d in Tumor Stroma and Tumorigenesis
    PPAR Research, vol. 2008, Article ID 534294, 5 pages, 2008
  2. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPAR  activation
    Journal of Experimental Medicine, 2007
  3. Ligand activation of peroxisome proliferator-activated receptor-ß/d(PPARß/d) inhibits cell growth of human N/TERT-1 keratinocytes
    Cellular Signalling, vol. 19, no. 6, pp. 1163–1171, 2007
  4. Sustained formation of a-(4-pyridyl-1-oxide)-N-tert-butylnitrone radical adducts in mouse liver by peroxisome proliferators is dependent upon peroxisome proliferator-activated receptor-a, but not NADPH oxidase
    Free Radical Biology and Medicine, vol. 42, no. 3, pp. 335–342, 2007
  5. The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-ß/d (PPARß/d)
    Free Radical Biology and Medicine, vol. 42, no. 8, pp. 1155–1164, 2007
  6. Deregulation of tumor angiogenesis and blockade of tumor growth in PPARß-deficient mice
    The EMBO Journal, vol. 26, no. 15, Article ID 7601803, 12 pages, 2007
  7. Transcriptional network governing the angiogenic switch in human pancreatic cancer
    Proceedings of the National Academy of Sciences, vol. 104, no. 31, pp. 12890–12895, 2007
  8. Alterations in Skin and Stratified Epithelia by Constitutively Activated PPARa
    Journal of Investigative Dermatology, vol. 126, no. 2, Article ID 5700056, 11 pages, 2006
  9. PPARß/d selectively induces differentiation and inhibits cell proliferation
    Cell Death and Differentiation, vol. 13, no. 1, Article ID 4401713, 7 pages, 2006
  10. The role of peroxisome proliferator-activated receptor-ß/d in epithelial cell growth and differentiation
    Cellular Signalling, vol. 18, no. 1, pp. 9–20, 2006
  11. Modes of Action and Species-Specific Effects of Di-(2-ethylhexyl)Phthalate in the Liver
    Critical Reviews in Toxicology, vol. 36, no. 5, pp. 459–479, 2006
  12. PPAR  regulates glucose metabolism and insulin sensitivity
    Proceedings of the National Academy of Sciences, vol. 103, no. 9, pp. 3444–3449, 2006
  13. BMC Cancer, vol. 6, no. 1, p. 113, 2006
  14. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity
    The Journal of Lipid Research, vol. 47, no. 9, pp. 2028–2041, 2006
  15. Ligand Activation of Peroxisome Proliferator-Activated Receptor ? Inhibits Colon Carcinogenesis
    Cancer Research, vol. 66, no. 8, pp. 4394–4401, 2006
  16. Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor   Modulation
    Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 3, pp. 585–591, 2005
  17. Peroxisome proliferator activated receptor   in colonic epithelial cells protects against experimental inflammatory bowel disease
    Gut, vol. 55, no. 8, pp. 1104–1113, 2005
  18. Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-?/? (PPAR?/?)
    Carcinogenesis, vol. 27, no. 5, pp. 1105–1112, 2005
  19. The Aryl Hydrocarbon Receptor Directly Regulates Expression of the Potent Mitogen Epiregulin
    Toxicological Sciences, vol. 89, no. 1, pp. 75–82, 2005
  20. The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
    Toxicological Sciences, vol. 90, no. 2, pp. 269–295, 2005
  21. Evidence that ligand binding is a key determinant of Ah receptor-mediated transcriptional activity
    Archives of Biochemistry and Biophysics, vol. 442, no. 1, pp. 59–71, 2005
  22. Differences in cell proliferation in rodent and human hepatic derived cell lines exposed to ciprofibrate
    Cancer Letters, vol. 222, no. 2, pp. 217–226, 2005
  23. Peroxisome proliferator-activated receptor-a and liver cancer: where do we stand?
    Journal of Molecular Medicine, vol. 83, no. 10, pp. 774–785, 2005
  24. Protective effects of a peroxisome proliferator-activated receptor-ß/d agonist in experimental autoimmune encephalomyelitis
    Journal of Neuroimmunology, vol. 168, no. 1-2, pp. 65–75, 2005
  25. Peroxisome proliferator–activated receptor-d attenuates colon carcinogenesis
    Nature Medicine, vol. 10, no. 5, Article ID nm1026, 2 pages, 2004
  26. PPARd status and Apc-mediated tumourigenesis in the mouse intestine
    Oncogene, vol. 23, no. 55, Article ID 1208143, 4 pages, 2004
  27. Peroxisome proliferator-activated receptor ? protects against alcohol-induced liver damage
    Hepatology, vol. 40, no. 4, pp. 972–980, 2004
  28. The United States-Japan workshop on: The role of nuclear receptors in carcinogenesis
    Molecular Carcinogenesis, vol. 41, no. 2, pp. 77–84, 2004
  29. PPAR /  potentiates PPAR -stimulated adipocyte differentiation
    The FASEB Journal, 2004
  30. PPAR  influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis
    Carcinogenesis, vol. 25, no. 9, pp. 1747–1755, 2004
  31. Role of peroxisome proliferator-activated receptor-? (PPAR?) in bezafibrate-induced hepatocarcinogenesis and cholestasis
    Carcinogenesis, vol. 26, no. 1, pp. 219–227, 2004
  32. Activation of Mouse and Human Peroxisome Proliferator-Activated Receptors (PPARs) by Phthalate Monoesters
    Toxicological Sciences, vol. 82, no. 1, pp. 170–182, 2004
  33. Expression of Base Excision DNA Repair Genes Is a Sensitive Biomarker for in Vivo Detection of Chemical-induced Chronic Oxidative Stress: Identification of the Molecular Source of Radicals Responsible for DNA Damage by Peroxisome Proliferators
    Cancer Research, vol. 64, no. 3, pp. 1050–1057, 2004
  34. Peroxisome Proliferator-activated Receptor ? (?)-dependent Regulation of Ubiquitin C Expression Contributes to Attenuation of Skin Carcinogenesis
    Journal of Biological Chemistry, vol. 279, no. 22, pp. 23719–23727, 2004
  35. Peroxisome Proliferator-activated Receptor  /  Regulates Very Low Density Lipoprotein Production and Catabolism in Mice on a Western Diet
    Journal of Biological Chemistry, vol. 279, no. 20, pp. 20874–20881, 2004
  36. Reduced Adiposity and Liver Steatosis by Stearoyl-CoA Desaturase Deficiency Are Independent of Peroxisome Proliferator-activated Receptor- 
    Journal of Biological Chemistry, vol. 279, no. 33, pp. 35017–35024, 2004
  37. Peroxisome Proliferator-activated Receptor- /  Inhibits Epidermal Cell Proliferation by Down-regulation of Kinase Activity
    Journal of Biological Chemistry, vol. 280, no. 10, pp. 9519–9527, 2004
  38. PPARa Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance
    Critical Reviews in Toxicology, vol. 33, no. 6, pp. 655–780, 2003
  39. Bezafibrate is a dual ligand for PPARa and PPARß: studies using null mice
    Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1632, no. 1-3, pp. 80–89, 2003
  40. Hepatic regeneration in peroxisome proliferator-activated receptor a-null mice after partial hepatectomy
    Hepatology Research, vol. 22, no. 1, pp. 52–57, 2002
  41. Targeted disruption of peroxisomal proliferator-activated receptor ß (d) results in distinct gender differences in mouse brain phospholipid and esterified FA levels
    Lipids, vol. 37, no. 5, pp. 495–500, 2002
  42. Induction of CYP3A Expression by Dehydroepiandrosterone: Involvement of the Pregnane X Receptor
    Drug Metabolism and Disposition, vol. 30, no. 5, pp. 570–575, 2002
  43. Pretreatment with troglitazone decreases lethality during endotoxemia in mice
    Journal of Endotoxin Research, vol. 8, no. 4, pp. 307–314, 2002
  44. PPAR- -Null Mice Are Protected From High-Fat Diet-Induced Insulin Resistance
    Diabetes, vol. 50, no. 12, pp. 2809–2814, 2001
  45. PPAR -Dependent Induction of Liver Microsomal Esterification of Estradiol and Testosterone by a Prototypical Peroxisome Proliferator
    Endocrinology, vol. 142, no. 8, pp. 3554–3557, 2001
  46. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice
    The Journal of Cell Biology, vol. 154, no. 4, pp. 799–814, 2001
  47. Evidence that reduction of hepatocyte growth factor (HGF) is not required for peroxisome proliferator-induced hepatocyte proliferation
    Carcinogenesis, vol. 22, no. 6, pp. 975–979, 2001
  48. Peroxisome Proliferator-activated Receptor alpha Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil
    Journal of Biological Chemistry, vol. 276, no. 7, pp. 4634–4639, 2001
  49. Peroxisome Proliferator-activated Receptor-alpha Regulates Lipid Homeostasis, but Is Not Associated with Obesity. STUDIES WITH CONGENIC MOUSE LINES
    Journal of Biological Chemistry, vol. 276, no. 42, pp. 39088–39093, 2001
  50. Adaptive Increase in Pyruvate Dehydrogenase Kinase 4 during Starvation Is Mediated by Peroxisome Proliferator-Activated Receptor a
    Biochemical and Biophysical Research Communications, vol. 287, no. 2, pp. 391–396, 2001
  51. Influence of conjugated linoleic acid on body composition and target gene expression in peroxisome proliferator-activated receptor a-null mice
    Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1533, no. 3, pp. 233–242, 2001
  52. Frequency of stromal lineage colony forming units in bone marrow of peroxisome proliferator-activated receptor-a-null mice
    Bone, vol. 26, no. 1, pp. 21–26, 2000
  53. Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARa and TNFa
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 448, no. 2, pp. 193–200, 2000
  54. Influence of peroxisome proliferator-activated receptor a on ubiquinone biosynthesis
    Journal of Molecular Biology, vol. 297, no. 3, pp. 607–614, 2000
  55. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis
    Carcinogenesis, vol. 21, no. 4, pp. 823–826, 2000
  56. Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor beta (delta )
    Molecular and Cellular Biology, vol. 20, no. 14, pp. 5119–5128, 2000
  57. Pharmacogenetics, vol. 10, no. 4, pp. 321–333, 2000
  58. Amelioration of TCDD-induced teratogenesis in aryl hydrocarbon receptor (AhR)-null mice
    Toxicological Sciences, vol. 47, no. 1, pp. 86–92, 1999
  59. Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice
    Toxicological Sciences, vol. 50, no. 1, pp. 82–89, 1999
  60. Peroxisomal and Mitochondrial Fatty Acid beta -Oxidation in Mice Nullizygous for Both Peroxisome Proliferator-activated Receptor alpha and Peroxisomal Fatty Acyl-CoA Oxidase. GENOTYPE CORRELATION WITH FATTY LIVER PHENOTYPE
    Journal of Biological Chemistry, vol. 274, no. 27, pp. 19228–19236, 1999
  61. Peroxisome Proliferator-activated Receptor alpha Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-kappa B and AP-1
    Journal of Biological Chemistry, vol. 274, no. 45, pp. 32048–32054, 1999
  62. Metabolism of Chloroform by Cytochrome P450 2E1 Is Required for Induction of Toxicity in the Liver, Kidney, and Nose of Male Mice
    Toxicology and Applied Pharmacology, vol. 160, no. 2, pp. 120–126, 1999
  63. Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor alpha (PPARalpha )
    Journal of Biological Chemistry, vol. 273, no. 10, pp. 5678–5684, 1998
  64. Expression of Putative Fatty Acid Transporter Genes Are Regulated by Peroxisome Proliferator-activated Receptor alpha and gamma Activators in a Tissue- and Inducer-specific Manner
    Journal of Biological Chemistry, vol. 273, no. 27, pp. 16710–16714, 1998
  65. Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver
    Carcinogenesis, vol. 19, no. 11, pp. 1989–1994, 1998
  66. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha
    Journal of the National Cancer Institute, vol. 90, no. 22, pp. 1702–1709, 1998
  67. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643
    Carcinogenesis, vol. 18, no. 11, pp. 2029–2033, 1997
  68. Polyunsaturated Fatty Acid Suppression of Hepatic Fatty Acid Synthase and S14 Gene Expression Does Not Require Peroxisome Proliferator-activated Receptor alpha
    Journal of Biological Chemistry, vol. 272, no. 43, pp. 26827–26832, 1997
  69. Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor alpha -deficient Mice
    Journal of Biological Chemistry, vol. 272, no. 43, pp. 27307–27312, 1997
  70. Comparative effects of essential and nonessential metals on preimplantation mouse embryo development in vitro
    Toxicology, vol. 116, no. 1-3, pp. 123–131, 1997
  71. PPARa Mediates Peroxisome Proliferator-Induced Transcriptional Repression of Nonperoxisomal Gene Expression in Mouse?
    Biochemical and Biophysical Research Communications, vol. 230, no. 1, pp. 155–158, 1997
  72. Di(2-Ethylhexyl) phthalate induces a functional zinc deficiency during pregnancy and teratogenesis that is independent of peroxisome proliferator-activated receptor-α
    Teratology, vol. 56, no. 5, pp. 311–316, 1997
  73. Enhancing effect of maternal zinc deficiency and137Cs ?-irradiation on the frequency of fetal malformations in mice
    Teratogenesis, Carcinogenesis, and Mutagenesis, vol. 17, no. 3, pp. 127–137, 1997
  74. The PPARa–leukotriene B4 pathway to inflammation control
    Nature, vol. 384, no. 6604, Article ID 384039a0, 4 pages, 1996
  75. Radiosensitive Target in the Mouse Embryo Chimera Assay: Implications That the Target Involves Autocrine Growth Factor Function
    Radiation Research, vol. 145, no. 6, p. 722, 1996
  76. Periconceptional zinc deficiency affects uterine3H-estradiol binding in mice
    Teratogenesis, Carcinogenesis, and Mutagenesis, vol. 15, no. 1, pp. 23–31, 1995
  77. Evidence That Murine Preimplantation Embryos Express Aryl Hydrocarbon Receptor
    Toxicology and Applied Pharmacology, vol. 134, no. 2, pp. 214–221, 1995
  78. Influence of antioxidants on cadmium toxicity of mouse preimplantation embryos in vitro
    Toxicology, vol. 99, no. 1-2, pp. 11–18, 1995
  79. Effect of a metallothionein antisense oligonucleotide on embryo development
    Reproductive Toxicology, vol. 9, no. 2, pp. 123–130, 1995
  80. Effect of the antihypertensive drug hydralazine on mineral metabolism in the rat
    Toxicology Letters, vol. 41, no. 3, pp. 193–202, 1988